Breaking News, Collaborations & Alliances

ThinkCyte and Axcelead DDP Enter Research Partnership

Will develop new approaches to screen candidate drugs for treating human diseases.

Author Image

By: Charlie Sternberg

Associate Editor

ThinkCyte and Axcelead Drug Discovery Partners (DDP) have entered a research partnership focused on developing new approaches to screen candidate drugs for treating human diseases.   The partnership will combine Ghost Cytometry, ThinkCyte’s AI-driven cell characterization and sorting technology, with Axcelead DDP’s phenotypic screening techniques and its diverse compound library of over 1.5 million candidate drugs to evaluate how these compounds change cellular phenotypes (their fo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters